The Parliament Magazine is pleased to be working with Eli Lilly and Company to mark the launch of their report ‘Seeking Solutions to a Global Health Crisis: Eli Lilly and Company’s Technology Transfer for Multidrug-Resistance Tuberculosis Medicines’.
Titled Leveraging Technology Transfer to Improve Access to Medicines, the event will feature a roundtable discussion involving key contributors from the development and scientific fields in the European Parliament on Wednesday 21 January 2015. MEP Nirj Deva has kindly agreed to host the event and lead the discussion.
Beginning in 2003, Lilly engaged in a 10-year effort to transfer its manufacturing technology, know-how and expertise for two medicines to address multidrug-resistant tuberculosis (MDR-TB). With 450,000 new cases of MDR-TB each year and resulting in 170,000 deaths, there is a clear global health imperative to find effective and sustainable solutions. Lilly’s technology transfer program sought to ensure a sustainable, global supply of high-quality medicines for MDR-TB.
A key component of Lilly’s effort was the transfer of technology, which involved donating manufacturing technology, know-how and expertise to manufacturers in four countries hardest hit by MDR-TB. The initiative made considerable impact on improving sustained access to high quality medicines for people with MDR‑TB.
This event marks the publication of a whitepaper, which documents how over the course of a decade, Lilly identified and collaborated with seven manufacturers to move manufacturing closer to people in need and help ensure a dependable supply of medicines.
The task might have seemed simple enough; donate the intellectual property rights and manufacturing know-how for two antibiotics identified as effective in the treatment of MDR-TB to companies in India, China, the Russian Federation and South Africa, where nearly 60 percent of the world’s MDR-TB cases are found.
A decade later, the project has demonstrated the huge potential of technology transfer in fighting TB as well as the challenges while also offering important insights for governments, companies and others considering technology transfers to solve complex global health problems.